330 related articles for article (PubMed ID: 29510530)
1. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
[TBL] [Abstract][Full Text] [Related]
2. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M
Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
[No Abstract] [Full Text] [Related]
4. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
[TBL] [Abstract][Full Text] [Related]
5. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
6. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke A; Gennatas S; Huang P; Jones RL
Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
Front Immunol; 2020; 11():851. PubMed ID: 32670260
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
[TBL] [Abstract][Full Text] [Related]
9. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
Fan J; Yang M; Huang B; Wang Z; Luo D; Zhang J; Zhang P; Shi H; Li Y; Nie X
Diagn Pathol; 2020 Jan; 15(1):8. PubMed ID: 32005261
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
Qi C; Pan F; Li J; Li Y; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
[TBL] [Abstract][Full Text] [Related]
11. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib.
Nannini M; Tarantino G; Indio V; Ravegnini G; Astolfi A; Urbini M; De Leo A; Santini D; Ceccarelli C; Gruppioni E; Altimari A; Castellucci P; Fanti S; Di Scioscio V; Saponara M; Gatto L; Pession A; Martelli PL; Casadio R; Pantaleo MA
Sci Rep; 2019 Feb; 9(1):2172. PubMed ID: 30778083
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
[TBL] [Abstract][Full Text] [Related]
15. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
[TBL] [Abstract][Full Text] [Related]
17. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
18. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P;
Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
